For research use only. Not for therapeutic Use.
Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs)[1].
Reltecimod (1.25-5 mg/kg; i.v.) TFA increases the survival rate of mice infected with different bacteria[1].
| Catalog Number | I040980 |
| Molecular Formula | C46H72N10O15S.xC2HF3O2 |
| Purity | ≥95% |
| Reference | [1]. Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669–1683 (2020). |
